Northern Trust Corp Sells 2,268 Shares of Krystal Biotech, Inc. $KRYS

Key Points

• Northern Trust Corp reduced its stake in Krystal Biotech, Inc. by selling 2,268 shares, which represents a 0.9% decrease, leaving them with approximately 260,000 shares valued at $46.88 million.
• The stock of Krystal Biotech recently increased by 0.5%, trading at $147.64, with a market cap of $4.27 billion and notable earnings that beat analyst expectations.
• Analysts maintain a positive outlook for Krystal Biotech, with several price target adjustments; the consensus target price is $210.38 and the stock holds an average rating of "Buy".

Northern Trust Corp cut its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 259,995 shares of the company's stock after selling 2,268 shares during the period. Northern Trust Corp owned 0.90% of Krystal Biotech worth $46,877,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Soleus Capital Management L.P. grew its holdings in Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock valued at $56,144,000 after buying an additional 141,400 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Krystal Biotech by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company's stock valued at $45,168,000 after buying an additional 7,344 shares during the last quarter. Nuveen LLC acquired a new stake in Krystal Biotech in the 1st quarter valued at approximately $42,223,000. Woodline Partners LP grew its holdings in Krystal Biotech by 23.0% in the 4th quarter. Woodline Partners LP now owns 221,102 shares of the company's stock valued at $34,638,000 after buying an additional 41,287 shares during the last quarter. Finally, Braidwell LP grew its holdings in Krystal Biotech by 18.9% in the 4th quarter. Braidwell LP now owns 200,500 shares of the company's stock valued at $31,410,000 after buying an additional 31,809 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the transaction, the insider owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 49,800 shares of company stock valued at $7,487,943 over the last three months. Corporate insiders own 13.70% of the company's stock.

Krystal Biotech Trading Up 0.9%

NASDAQ:KRYS traded up $1.30 during mid-day trading on Tuesday, hitting $149.00. The company's stock had a trading volume of 317,181 shares, compared to its average volume of 287,918. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $207.84. The company has a market capitalization of $4.31 billion, a price-to-earnings ratio of 30.28 and a beta of 0.66. The stock has a fifty day moving average of $146.13 and a 200-day moving average of $154.24.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on KRYS shares. Guggenheim lowered their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. Chardan Capital cut their price objective on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research report on Friday, August 22nd. Bank of America cut their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Friday, August 22nd. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $210.38.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).